Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.43 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.43 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.34 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18385732 | 0.86 | GRIK1 (0.33) | GRIK1GRIK2GRIK3GRIK5 | |
| SCHEMBL18531924 | 0.82 | GRIK1 (0.45) | GRIK1GRIK2GRIK3GRIK5GRM2 | |
| SCHEMBL19115629 | 0.82 | GRIK1 (0.45) | GRIK1GRIK2GRIK3GRIK5GRM2 | |
| SCHEMBL18392135 | 0.81 | GRM2 (0.33) | GRM2GRM6GRM3 | |
| SCHEMBL12191633 | 0.79 | GRIK1 (0.43) | GRIK1GRIK2GRIK3GRIK5GRM2 | |
| SCHEMBL8973389 | 0.79 | GRM2 (0.57) | GRM2GRM6GRM3 | |
| SCHEMBL18385734 | 0.77 | — | — | |
| SCHEMBL19103704 | 0.75 | GRIK1 (0.34) | GRIK1GRIK2GRIK3GRIK5GRM2 | |
| SCHEMBL19075530 | 0.72 | RIPK1 (0.34) | GRIK1GRIK2GRIK3GRIK5GRM2 | |
| SCHEMBL2209193 | 0.72 | GRM2 (0.36) | GRIK1GRIK2GRIK3GRIK5GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938301-B2 | Dihydropyrimido fused ring derivative as HBV inhibitor | QILU PHARMACEUTICAL CO., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-9938301-B2 | Dihydropyrimido fused ring derivative as HBV inhibitor | QILU PHARMACEUTICAL CO., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170197986-A1 | DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197986-A1 | DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR | TMBIM6, HAVCR2, HDGF | GRIK1 3975/4885GRIK2 4250/4885GRIK3 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.